FTC cracking down on “pay-for-delay” generic drug deals.

Bloomberg News (6/23, McLaughlin) reports that the Federal Trade Commission (FTC), bolstered by a recent Supreme Court decision, has “opened new investigations into agreements between generic and brand-name drugmakers that may lead the agency to sue for disgorgement of revenues,” according to Markus Meier, head of the FTC’s healthcare division. Citing regulatory filings, Bloomberg News says that Forest Laboratories and Endo International are among the companies being probed. Citing the Supreme Court decision from last June, Meier said the FTC had opened new probes, but did not provide details.